|
1
|
Schild SE and Vokes EE: Pathways to
improving combined modality therapy for stage III nonsmall-cell
lung cancer. Ann Oncol. 27:590–599. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fiala O, Šorejs O, Pešek M and Fínek J:
Immunotherapy in the treatment of lung cancer. Klin Onkol. 30
(Supplementum3):22–31. 2017.(In Czech). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hontscha C, Borck Y, Zhou H, Messmer D and
Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the
international registry on CIK cells (IRCC). J Cancer Res Clin
Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dougan M and Dranoff G: Immune therapy for
cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li R, Wang C, Liu L, Du C, Cao S, Yu J,
Wang SE, Hao X, Ren X and Li H: Autologous cytokine-induced killer
cell immunotherapy in lung cancer: A phase II clinical study.
Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tian H, Shi G, Yang G, Zhang J, Li Y, Du
T, Wang J, Xu F, Cheng L, Zhang X, et al: Cellular immunotherapy
using irradiated lung cancer cell vaccine co-expressing GM-CSF and
IL-18 can induce significant antitumor effects. BMC Cancer.
14:482014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tse BW, Russell PJ, Lochner M, Förster I
and Power CA: IL-18 inhibits growth of murine orthotopic prostate
carcinomas via both adaptive and innate immune mechanisms. PLoS
One. 6:e242412011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng JN, Pei DS, Mao LJ, Liu XY, Sun FH,
Zhang BF, Liu YQ, Liu JJ, Li W and Han D: Oncolytic adenovirus
expressing interleukin-18 induces significant antitumor effects
against melanoma in mice through inhibition of angiogenesis. Cancer
Gene Ther. 17:28–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jia Y, Zang A, Jiao S, Chen S and Yan F:
The interleukin-18 gene promoter-607 A/C polymorphism contributes
to non-small-cell lung cancer risk in a Chinese population. Onco
Targets Ther. 9:1715–1719. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Timperi E, Focaccetti C, Gallerano D,
Panetta M, Spada S, Gallo E, Visca P, Venuta F, Diso D, Prelaj A,
et al: IL-18 receptor marks functional CD8+ T cells in non-small
cell lung cancer. Oncoimmunology. 6:e13283372017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Senju H, Kumagai A, Nakamura Y, Yamaguchi
H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura
H, et al: Effect of IL-18 on the expansion and phenotype of human
natural killer cells: Application to cancer immunotherapy. Int J
Biol Sci. 14:331–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshimitsu M, Sato T, Tao K, Walia JS,
Rasaiah VI, Sleep GT, Murray GJ, Poeppl AG, Underwood J, West L, et
al: Bioluminescent imaging of a marking transgene and correction of
Fabry mice by neonatal injection of recombinant lentiviral vectors.
Proc Natl Acad Sci USA. 101:16909–16914. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamura M, Modlin RL, Ohmen JD and Moy
RL: Local expression of antiinflammatory cytokines in cancer. J
Clin Invest. 91:1005–1010. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Asselin S, Conjeaud H, Minty A, Fradelizi
D and Breban M: Stable polarization of peripheral blood T cells
towards type 1 or type 2 phenotype after polyclonal activation. Eur
J Immunol. 28:532–539. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chechlińska M, Duma A, Swierkowska K,
Kamińska J and Steffen J: Sera of lung cancer patients affect the
release of Th1, Th2 and monocyte-derived cytokines, and the
expression of IL-2Ralpha by normal, stimulated mononuclear cells.
Cell Mol Biol Lett. 9:69–81. 2004.PubMed/NCBI
|
|
17
|
Yamashita K, Iwasaki T, Tsujimura T,
Sugihara A, Yamada N, Ueda H, Okamura H, Futani H, Maruo S and
Terada N: Interleukin-18 inhibits lodging and subsequent growth of
human multiple myeloma cells in the bone marrow. Oncol Rep.
9:1237–1244. 2002.PubMed/NCBI
|
|
18
|
Yamanaka R and Xanthopoulos KG: Induction
of antigen-specific immune responses against malignant brain tumors
by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
DNA Cell Biol. 24:317–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park S, Cheon S and Cho D: The dual
effects of interleukin-18 in tumor progression. Cell Mol Immunol.
4:329–335. 2007.PubMed/NCBI
|
|
20
|
Nakamura Y, Yamada N, Ohyama H, Nakasho K,
Nishizawa Y, Okamoto T, Futani H, Yoshiya S, Okamura H and Terada
N: Effect of interleukin-18 on metastasis of mouse osteosarcoma
cells. Cancer Immunol Immunother. 55:1151–1158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu T, Hao XS, Ren XB and Zhang HL: Killing
effect of interleukin-18-enhanced FasL-expressing colon cancer
cells on human hepatocytes in vitro. Zhonghua Zhong Liu Za Zhi.
32:659–662. 2010.(In Chinese). PubMed/NCBI
|
|
22
|
Napetschnig J and Wu H: Molecular basis of
NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Slattery ML, Mullany LE, Sakoda L,
Samowitz WS, Wolff RK, Stevens JR and Herrick JS: The NF-κB
signalling pathway in colorectal cancer: Associations between
dysregulated gene and miRNA expression. J Cancer Res Clin Oncol.
144:269–283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang L, Zhou Y, Li Y, Zhou J, Wu Y, Cui Y,
Yang G and Hong Y: Mutations of p53 and KRAS activate NF-κB to
promote chemoresistance and tumorigenesis via dysregulation of cell
cycle and suppression of apoptosis in lung cancer cells. Cancer
Lett. 357:520–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang
L, Huang W, Huang L and Wang Q: Interleukin-32 contributes to
invasion and metastasis of primary lung adenocarcinoma via
NF-kappaB induced matrix metalloproteinases 2 and 9 expression.
Cytokine. 65:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang H, Zhang Z and Xu Y: Effects of
interleukin-18 on asthmatic airway inflammation and nuclear factor
kappa-B in murine models. Chin Med J (Engl). 116:323–327.
2003.PubMed/NCBI
|
|
28
|
Kanda N, Shimizu T, Tada Y and Watanabe S:
IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and
CXCL11 in human keratinocytes. Eur J Immunol. 37:338–350. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Robertson MJ, Kirkwood JM, Logan TF, Koch
KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J and Dar
MM: A dose-escalation study of recombinant human interleukin-18
using two different schedules of administration in patients with
cancer. Clin Cancer Res. 14:3462–3469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tarhini AA, Millward M, Mainwaring P,
Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM and
Kirkwood JM: A phase 2, randomized study of SB-485232, rhIL-18, in
patients with previously untreated metastatic melanoma. Cancer.
115:859–868. 2009. View Article : Google Scholar : PubMed/NCBI
|
